REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
02/16/2026
Back to search
Official data from USPTO
NOURIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
02/17/2026
Trademark type
Word
Nice classes
1, 5
Filing date
01/21/2020
Registration date
02/16/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/16/2021
Last transaction
02/17/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
10/19/2020
First use in commerce
10/19/2020
Drawing code
4
Owner type
03
Owner location
Vienna, VA
Examiner
MAYES, LAURIE ANN
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Nour Heart, Inc.
Representatives
Shuo Che Chou SINORICA LLC DBA THOUGHTS TO PAPER
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
protein arrays for research purposes; gene-based RNA molecular network being RNA sequences for research purposes; protein arrays for diagnosing of heart-related diseases anginaheart attackcardiac and non-cardiac chest painheart failurecardiovascular diseasesacute coronary syndromescoronary artery diseaseischemic cardiac diseasesubclinical or silent ischemialow-grade myocardial ischemiaheart transplantation for cardiac allograft inflammationmonitor disease progressionseverity of heart damagerisk assessment and prognosisdisease progressionmyocardial cell damagepatients at-risk for coronary artery diseasepredict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseasesall of the foregoing for research purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases anginaheart attackcardiac and non-cardiac chest painheart failurecardiovascular diseasesacute coronary syndromescoronary artery diseaseischemic cardiac diseasesubclinical or silent ischemialow-grade myocardial ischemiaheart transplantation for cardiac allograft inflammationmonitor disease progressionseverity of heart damagerisk assessment and prognosisdisease progressionmyocardial cell damagepatients at-risk for coronary artery diseasepredict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseasesall of the foregoing for research use; diagnostic biomarker reagents for research purposes; protein arrays of biomarker reagents for research purposes; gene-based RNA molecular network biomarker reagents for research purposes; protein arrays and gene-based RNA molecular network biomarker reagents for research purposes; tissue-derived diagnostic biomarker reagents for research purposes; cardiac-derived diagnostic biomarker reagents for research purposes
Class 5
protein arrays for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for medical diagnosis purposes; protein arrays for diagnosing of heart-related diseases anginaheart attackcardiac and non-cardiac chest painheart failurecardiovascular diseasesacute coronary syndromescoronary artery diseaseischemic cardiac diseasesubclinical or silent ischemialow-grade myocardial ischemiaheart transplantation for cardiac allograft inflammationmonitor disease progressionseverity of heart damagerisk assessment and prognosisdisease progressionmyocardial cell damagepatients at-risk for coronary artery diseasepredict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseasesall of the foregoing for medical diagnosis purposes; gene-based RNA molecular network being RNA sequences for diagnosing of heart-related diseases anginaheart attackcardiac and non-cardiac chest painheart failurecardiovascular diseasesacute coronary syndromescoronary artery diseaseischemic cardiac diseasesubclinical or silent ischemialow-grade myocardial ischemiaheart transplantation for cardiac allograft inflammationmonitor disease progressionseverity of heart damagerisk assessment and prognosisdisease progressionmyocardial cell damagepatients at-risk for coronary artery diseasepredict drug therapy response on heart tissue (myocardial cell damage) in clinical trials as well as other diseasesall of the foregoing for medical use; diagnostic biomarker reagents for medical purposes; protein arrays of biomarker reagents for medical diagnosis purposes; gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; protein arrays and gene-based RNA molecular network biomarker reagents for medical diagnosis purposes; tissue-derived diagnostic biomarker reagents for medical purposes; cardiac-derived diagnostic biomarker reagents for medical purposes
Publications
History of USPTO decisions and trademark events.
22 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
02/16/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/15/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/14/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
01/14/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
01/13/2021
IUAF
USE AMENDMENT FILED
12/22/2020
EISU
TEAS STATEMENT OF USE RECEIVED
12/22/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
08/04/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/09/2020
PUBO
PUBLISHED FOR OPPOSITION
06/09/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/20/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/05/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/25/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/24/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/24/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/13/2020
GNRT
NON-FINAL ACTION E-MAILED
04/13/2020
CNRT
NON-FINAL ACTION WRITTEN
04/13/2020
DOCK
ASSIGNED TO EXAMINER
04/08/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/25/2020
NWAP
NEW APPLICATION ENTERED
01/24/2020
Continuous trademark protection
Get notified about every new filing that threatens NOURIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.